Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-04-07

Tempus AI, Inc.

Tempus sells genomic testing, clinical workflow software, and de-identified data and analytics products to providers, health systems, and life sciences customers.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A Regulated Data Flywheel Seeking Leverage

This is a bet that a trusted healthcare data-and-workflow network can earn better-than-lab economics without owning frontier AI. The upside is meaningful if validation, enterprise monetization, and cash conversion improve together; the downside is a re-rating toward diagnostics peers.

Analysis

Thesis

Tempus owns a rare combination of regulated data rights, diagnostic throughput, and physician workflow placement; if it converts that position into recurring evidence and operating-layer revenue while proving cash discipline, it can compound into a materially larger healthcare AI platform by 2031.

Last Economy Alignment

Cheaper cognition makes Tempus' linked clinical and molecular data more valuable, and its workflow embed is harder to displace than generic software; the main limiter is proof of monetization in regulated care.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.5x (from 5 most recent analyses)

Reasoning

The upside case does not require Tempus to win frontier AI. It requires three things: sustained diagnostics share gains, clear conversion of data and workflow products into recurring enterprise revenue, and visible operating leverage so growth stops depending on external capital. If those three line up, the market can keep valuing Tempus as a scarce healthcare data-rights compounder rather than a lab with AI features.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not whether Tempus can build AI products; it is whether clinical proof, reimbursement, contract conversion, and cost discipline arrive fast enough for investors to keep treating it as a premium healthcare data platform. If those gates slip, the business can still grow while the multiple compresses toward diagnostics peers.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

April 1 ALERT results gave Tempus Next a real clinical validation point outside oncology, showing workflow alerts can change treatment actions rather than just surface information.
The ALERT readout improves the case for cardiology adjacency, but commercialization still depends on provider deployment and contract capture, not the trial result alone.
No new guidance or financing action appeared in the last week from reviewed official sources, so the next likely repricing gate remains Q1 execution versus the 2026 revenue and profitability guide.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.68

They control patient data rights and doctor workflow touchpoints, so cheaper AI makes their information asset more useful instead of obsolete. The risk is that healthcare buyers only pay for tools that prove better outcomes, cleaner compliance, and real budget savings.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$80.14

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research